Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis study demonstrates migraine prevention benefits of erenumab

Novartis study demonstrates migraine prevention benefits of erenumab

30th November 2017

Novartis has published the findings of a new clinical study showing the significant benefits that its drug erenumab can deliver for migraine sufferers.

The New England Journal of Medicine has published positive results from the six-month phase III STRIVE study, which evaluated erenumab in the prevention of episodic migraine compared to placebo.

Erenumab was shown to deliver clinically meaningful and statistically significant benefits over six months, with reduced migraine days and acute medication use. Treatment with the drug was also well tolerated, with a safety profile comparable to placebo.

Additionally, the data showed that erenumab patients had their migraine days cut by at least half – nearly a threefold better performance than placebo – and reported reduced physical impairment and improved ability to participate in daily activities.

Vas Narasimhan, global head of drug development and chief medical officer for Novartis, said: "The results of the STRIVE study add to the evidence for the significant, consistent benefits of erenumab seen across the spectrum of chronic and episodic migraine, including patients who failed on previous preventive treatments."

Erenumab is the first and only fully human monoclonal antibody of its kind, and has been designed to specifically block the CGRP receptor that plays a crucial role in migraine activation.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.